Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.89 USD 0.29 ( 4.39%)
Last update at 2026-11-06T21:00:00Z
VOLUME
583894
Market Cap
535.86M

Momentum Score

…

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.52
Low
6.89
High
52 Week Price Range
5.16
Low
9.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
6.60
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-66.70%
Net Debt
-80.41M
ROCE
-47.92%
Diluted EPS TTM
-1.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -38.59M -25.74M -21.78M -18.99M -24.34M
Minority interest 0.03M 0.24M 0.75M 0.50M 0.30M
Net income -38.58M -25.50M -21.25M -18.49M -23.96M
Selling general administrative 17.10M 10.92M 5.63M 3.99M 8.12M
Selling and marketing expenses - - 2.37M 0.30M 0.08M
Gross profit -0.33M -0.16M -0.21M -0.19M -0.11M
Reconciled depreciation 0.24M 0.17M 0.16M 0.15M 0.09M
Ebit -38.59M -25.14M -20.90M -18.01M -17.91M
Ebitda -38.35M -24.97M -20.78M -17.86M -17.85M
Depreciation and amortization 0.24M 0.17M 0.12M 0.15M 0.06M
Operating income -38.43M -27.00M -20.97M -17.62M -18.38M
Other operating expenses 38.43M 27.00M 20.97M 17.62M 18.38M
Interest expense 0.00M 0.60M 0.88M 0.98M 1.16M
Tax provision 0.02M 0.00M 0.04M 0.00M -
Interest income 1.41M 1.16M 0.86M 0.43M 0.05M
Net interest income 1.41M 0.56M -0.31M -0.55M -0.97M
Income tax expense 0.02M 0.00M 0.03M 0.93M -1.34M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 38.43M 27.00M 20.97M 17.62M 18.38M
Cost of revenue 0.33M 0.16M 0.21M 0.19M 0.11M
Total other income expense net -0.15M 1.26M -0.81M -1.37M -5.96M
Net income from continuing ops -38.61M -25.74M -28.97M -18.99M -18.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 86.15M 34.94M 15.26M 25.89M 31.22M
Other current assets 3.86M 1.11M 0.20M 0.44M 0.70M
Total liab 5.70M 3.10M 14.59M 16.13M 12.10M
Total stockholder equity 82.04M 33.40M 1.67M 10.54M 19.95M
Other current liab 5.55M 3.03M 6.69M 3.97M 2.11M
Common stock 195.41M 116.36M 69.96M 96.13M 77.65M
Capital stock 225.15M 148.07M 92.91M 71.00M 63.30M
Retained earnings -169.58M -131.00M -79.43M -104.63M -74.26M
Other assets - - 6.31M - -
Cash 80.56M 33.10M 14.56M 24.73M 20.89M
Total current liabilities 5.63M 3.10M 14.59M 4.14M 2.27M
Current deferred revenue - - 0.00M - -
Net debt -80.41M -33.03M -6.69M -12.56M -10.90M
Short term debt 0.08M 0.07M 7.87M 0.18M 0.15M
Short long term debt - - 10.40M 0.08M 0.07M
Short long term debt total 0.15M 0.07M 7.87M 12.17M 9.99M
Other stockholder equity 28.52M 20.50M 13.18M 22.81M 0.00M
Total current assets 85.10M 34.44M 14.91M 25.17M 30.60M
Short term investments - - -6.16M 0.00M 9.01M
Net receivables 0.67M 0.23M 0.14M 0.09M 0.43M
Long term debt - - - 8.80M 7.27M
Inventory - - 0.00M 0.00M 0.00M
Accumulated other comprehensive income -2.04M -4.16M -2.04M -3.77M 16.56M
Non currrent assets other 0.06M 0.08M 0.01M 0.00M 0.03M
Non current assets total 1.05M 0.51M 0.35M 0.72M 0.62M
Capital lease obligations 0.15M 0.07M 0.05M 0.10M 0.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.08M -0.07M 9.83M -14.45M
Total cashflows from investing activities -0.60M -0.08M -0.06M 9.83M -11.42M
Net borrowings 0.00M -9.14M -0.08M -0.14M 9.48M
Total cash from financing activities 77.33M 45.78M 15.87M 10.80M 39.46M
Net income -39.22M -25.74M -21.81M -18.99M -18.18M
Change in cash 47.30M 13.76M 0.81M 5.73M 16.40M
Begin period cash flow 33.05M 19.34M 13.75M 12.53M 0.12M
End period cash flow 80.35M 33.10M 14.56M 18.26M 16.52M
Total cash from operating activities -29.03M -29.99M -15.62M -14.40M -11.58M
Issuance of capital stock 73.89M 54.56M 15.89M 10.64M 37.83M
Depreciation 0.24M 0.17M 0.12M 0.15M 0.09M
Other cashflows from investing activities - 0.03M -0.00M 0.00M -3.97M
Change to inventory - - -0.58M -1.32M -
Change to account receivables -0.44M -0.10M -0.08M 0.23M 0.15M
Other cashflows from financing activities - 0.36M 3.97M 0.31M -0.07M
Capital expenditures 0.60M 0.10M 0.06M 0.24M 0.34M
Change in working capital -0.73M -6.76M 4.03M 1.51M -0.17M
Stock based compensation 9.04M 3.22M 1.06M 1.43M 4.21M
Other non cash items 10.68M -0.88M 0.98M 1.50M 6.68M
Free cash flow -29.63M -30.10M -15.68M -14.63M -11.92M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc. Common Stock		 0.29
4.39%		 6.89 - - - 4.92 -2.85
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

250 590 3968

https://www.eupraxiapharma.com

49

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer 1969
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Corporate Development Officer NA
Ms. Wajida Leclerc B.A., CCP, CHRP Executive Vice President Corporate Services & People 1960
Mr. Alex Therien Executive VP of R&D NA
Dr. Jeymi Tambiah M.S. Chief Medical Officer NA
Dr. Jeffrey Millard Ph.d. Executive Vice President of Technical Operations 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…